Invokana Lawsuit Plaintiffs Alleging Diabetic Ketoacidosis Side Effects Linked To Drug See Support From Clinical Studies

February 22, 2016 – – TheProductLawyers.com reports on recent news linking diabetes type-2 drug Invokana to the potential for higher rates of diabetic ketoacidosis than other types of SGLT2 inhibitor class drugs during clinical trials. For those using the drug, medical experts are currently working to get out additional information which, they say, could help better manage the risks of developing diabetic ketoacidosis, a dangerous and potentially fatal health condition. This information was recently discussed in an article published in Diabetes Care from the American Heart Association.

In the article, authors Dr. Julio Rosenstock and Elle Ferrannini recommend that lowering the risk of diabetic ketoacidosis should begin with physicians, who should closely evaluate patients who may have risk factors for the condition. They advise that patients with risk factors be closely monitored for any metabolic changes. They also note that risk factors for the development of diabetic ketoacidosis include patients who have had another illness recently, who may have decreased food or liquid intake, a history of alcohol use, latent autoimmune diabetes, long-standing diabetes with B-cell insufficiency, and other factors.

Within their report, the researchers also indicate that during clinical trials on Invokana and other similar SGLT2 inhibitor class drugs, the incidence of development of diabetic ketoacidosis was significantly increased for patients using Invokana than for those using any of the other drugs. The U.S. Food and Drug Administration (FDA) has also noted that adverse event reports indicating the development of diabetic ketoacidosis in Invokana and other SGLT2 inhibitor drug patients consisted of 20 cases. Shortly after this warning, European health officials also announced that 101 cases of diabetic ketoacidosis had been reported across the world.

Diabetic ketoacidosis is a serious medical condition which can occur when acid levels in the bloodstream get too high. Patients suffering from this disorder typically require hospitalization, and, if left untreated for too long, can become comatose or pass away from complications. A common problem is that physicians are used to looking for elevated blood sugar levels to help indicate the development of ketoacidosis in patients, however, those who have developed diabetic ketoacidosis linked to Invokana or other SGLT2 inhibitors often only show slightly elevated blood sugar levels and very few other symptoms.

The attorneys at Banville Law, who sponsor online resource page TheProductLawyers.com, are currently working to help anyone who may have used Invokana or other SGLT2 inhibitor drugs and who have developed medical conditions which they connect to the treatment. These individuals may be entitled to legal action and substantial compensation. To help encourage potential victims to seek justice, the attorneys at Banville Law are currently offering free legal consultations for affected individuals.

To request additional information, or to ask questions, please contact the attorneys at Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008278